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Inherited renal disease is a leading cause of morbidity and mortality in pediatric
nephrology. High throughput advancements in genomics have led to greater understanding of the biologic underpinnings of these diseases. However, the underlying
genetic changes explain only part of the molecular biology that contributes to disease
manifestation and progression. Other omics technologies will provide a more complete
picture of these cellular processes. This review discusses these omics technologies in the
context of pediatric renal disease.

Introduction
In 1985, researchers identiﬁed the ﬁrst renal disease gene,
polycystic kidney disease 1 (PKD1), responsible for autosomal
dominant polycystic kidney disease (ADPKD), but renal
gene discovery progressed slowly prior to sequencing of
the human genome and development of high throughput
next generation sequencing (NGS).1,2 Currently, there are
more than 1,200 genes associated with renal disease and
development, largely owing to advancements in genomic
technology.3 This collection of genes includes more than
160 genes associated with rare inherited kidney diseases
that contribute greatly to morbidity and mortality in pediatric renal disease.1,4 Investigators and clinicians are using this
technology to diagnose Mendelian diseases such as Alport
syndrome, search for novel pathogenic genes in diseases such
as focal segmental glomerulosclerosis (FSGS), and identify
risk genes in hypertension.5–8 These genetic discoveries allow
for further elucidation of the mechanistic underpinnings of
inherited kidney disease.
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However, genomics and NGS technology address only one
aspect of the molecular biology. Other high throughput omics
technologies attempt to address the missing pieces and
complete the biological story. The high throughput methods
of epigenomics and transcriptomics utilize basic NGS principals to describe regulation of genomic information, while
proteomics and metabolomics use mass spectrometry (MS) to
explore the downstream effects. This knowledge promises to
improve prognostication and will translate into more effective treatments for children afﬂicted with these diseases.1,9
However, the genetic complexity of many of these diseases
coupled with immature high throughput research methodology may lead to improper application and inaccurate
conclusions.10
This review discusses the available omics techniques,
highlighting weaknesses and illustrating their use in pediatric nephrology research. It will not review microarray technology but will instead focus on NGS and MS high throughput
methods. In addition, it will brieﬂy discuss systems biology
for high throughput data analysis and some of the model
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systems used to test these integrative approaches in pediatric
nephrology.

General Study Design Considerations for
Omics Data
Biostatistical Considerations
Each omics ﬁeld examines a speciﬁc aspect of a molecular
pathway and as a result, multiple different techniques exist to
study each element (►Table 1). These techniques require
unique biostatistical methods and software to analyze the
data. A detailed review of these methods and software is
beyond the scope of this article, but this information may be
found elsewhere.10–22 However, researchers should consider
some basic principles when using omics data. All experiments
should apply appropriate power analyses prior to implementation. Power calculations must consider the genomic or
biologic space interrogated to determine adjustments in
the false discovery rates or p values due to multiple testing.10,22–24 This adjustment relies on understanding the
interdependency of the different tests which is often difﬁcult
to estimate. Thus, researchers must decide how conservative
to be in their adjustment of type I error rates.11,23 In genomic
studies, researchers must consider the allele frequency, the
effect size of a variant, and the genetic and phenotypic
heterogeneity of the trait of interest when considering power
estimates.10 For omics studies of quantitative traits, power
calculations should include consideration of the biological
and measurement variability. Finally, the testing software
selected must accommodate the massive amount and format
of data generated from the experiments and be speciﬁc for the
type of omics question being answered.11,24,25
In addition to these common considerations, there are
speciﬁc considerations unique to each high throughput method. Researchers must consider genomic unit for comparison
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as this determines the number of tests performed and is
important for the choice of downstream analysis.23 In genomic association studies of rare variants for complex traits, rare
variants are often collapsed into units based on gene parameters, linkage disequilibrium, or simply by proximity using
sliding windows of a particular length.11 Unlike genomic
studies with low intra-sample variability due to homogeneity
of cells and the relatively static nature of DNA, the other omics
ﬁelds have much more intra-sample and inter-sample variability. Researchers must consider a statistical test’s ability to
capture and describe this variability when selecting their
statistical approach.12 Many of these studies are measuring
quantitative traits. The addition of more samples will help
improve some of the technical biases of the study and
decrease variability for the measured trait. The addition of
sample replicates will help control for within-sample
biases.12,16,18,19,22

Utilizing Preexisting Datasets
Many omics studies use previously generated datasets for
additional affected individuals, as validation cohorts, or as
reference datasets due to the signiﬁcant costs of generating
data and the rarity of some conditions. There are many
publicly accessible databases/repositories and ongoing initiatives to establish more (►Table 2). However, this pooling of
data from multiple sites introduces the possibility of population stratiﬁcation and systematic differences in high throughput methods and quality control.10
Phenotypic data plays an important role in identifying the
underlying cause and the affected molecular pathways that
cause inherited renal disease.26 Often phenotypic data stored
in databases and repositories are sparse or poorly categorized
and thus may confound study results.10 In attempts to
improve omics data sharing and transparency, experts are
establishing guidelines for both study publication and

Table 1 Overview of omics data and experimental approaches
Technology

Type of data

Common approaches

References

Genomics

Gene number, structure, function, and
organization

Targeted gene panels, WES, WGS

32

Epigenomics

Regulatory elements: transcription factor
binding sites, methylation patterns,
nucleosome location, chromatin accessibility,
histone modiﬁcation

ChIP-seq, Methyl-seq, MethylC-seq,
MeDip-seq, MBD-seq, ChIA-PET, ATAC-seq,
FAIRE-seq, DNase-seq, MNase-seq

61,66

Transcriptomics

All RNA species including regulatory RNA,
gene expression levels, posttranscriptional
modiﬁcations

RNA-seq, NET-seq, CAPTURE-seq
CLIP-seq, iCLIP, and PAR-CLIP

74,100

Proteomics

All proteins, protein–protein interaction

LC-MS

101

Metabolomics

Peptides, amino acids, nucleic acids, and
organic acids

LC-MS

91

Abbreviations: ATAC-seq, assay for transposase-accessible chromatin using sequencing; CAPTURE-seq, RNA capture sequencing; ChIA-PET, chromatin
interaction analysis by paired-end tag sequencing; ChIP-seq, chromatin immunoprecipitation sequencing; CLIP-seq, cross-linking immunoprecipitation sequencing; DNase-seq, DNase I sequencing; FAIRE-seq, formaldehyde-assisted isolation of regulatory elements; iCLIP, individual-nucleotide
resolution cross-linking immunoprecipitation; LC-MS, liquid chromatography-mass spectrometry; MDB-seq, methylated DNA binding domain
sequencing; MeDip-seq, methylated DNA immunoprecipitation sequencing; MNase-seq, micrococcal nuclease sequencing; NET-seq, native
elongating transcript sequencing; PAR-CLIP, photoactivatable-ribonucleoside-enhanced cross-linking and immunoprecipitation; WES, whole exome
sequencing; WGS, whole genome sequencing.
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Table 2 Common and nephrologic databases with available omics datasets
Database

Data

Reference

General
1000 Genomes

Low coverage human genome datasets

102

MGI Mouse Genome

Integrated genetic, genomic, and biologic information from
laboratory mice

103

Human Epigenome Project

DNA methylation in human tissues

104

ENCODE

Functional genomic elements in multiple human tissues

105

Mouse Reference Transcriptome Project

Gene expression data on multiple mouse tissues

106

PRIDE

Proteomic datasets from large number of organisms

107

Human Metabolome Database

Detailed metabolites in the human body

108

European Renal cDNA Bank

Gene expression data from renal biopsies

109

EURenOmics

Biorepository and phenotypic data for rare kidney diseases

110

GUDMAP

Gene expression datasets for genitourinary tract of mice

111,112

NEPTUNE

Biorepository and phenotypic data on patients with proteinuria

113

Nephrology

Abbreviations: ENCODE, Encyclopedia of DNA Elements; GUDMAP, Genitourinary Development Molecular Anatomy Project; NEPTUNE, Nephrotic
Syndrome Study Network; PRIDE, PRoteomics IDEntiﬁcations database.

database deposition that will hopefully help clarify these
issues.10,27–30 Without this clariﬁcation, systematic confounding of data introduced by sequencing platforms and
bioinformatics pipelines will lead to misinterpretation of
results.

Basics of Next Generation Sequencing
NGS also known as massively parallel sequencing revolutionized the ﬁeld of genomics. These methods create the foundation for a wide variety of experimental approaches in
genomics, epigenomics, and transcriptomics. The basic approach to NGS starts with DNA fragmentation and platformspeciﬁc adapter ligation to create a DNA library, which can be
ampliﬁed later using polymerases if desired. The sequencing
reactions then take place in situ on a solid surface containing
complimentary sequence to the adapters. This in situ sequencing generates a massive number of sequencing reads
simultaneously (i.e., in parallel), vastly improving the efﬁciency compared with Sanger sequencing.31 NGS platforms
perform sequencing and nucleotide detection in one ﬂuid
process; nucleotides are added, a detection step is performed,
a wash step occurs, and the process repeats itself.31,32 These
improvements decrease the per base sequencing costs and
time compared with Sanger sequencing, allowing for larger
adoption of NGS in research.4

Sequencing Platforms
All of the NGS high throughput methods require choice of a
sequencing platform. Most platforms have built-in ﬂexibility
to perform sequencing for genomic, epigenomic, and transcriptomic experiments. While all NGS technologies have
relatively high per base sequencing error rates and rely on
Journal of Pediatric Genetics
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increased coverage to overcome these errors, recent comparisons of commonly used platforms demonstrate variable
performance.33,34 Common problems with this technology
include short read lengths causing issues with alignment in
repetitive regions of the genome, poor coverage in GC rich
areas, and ampliﬁcation bias for those technologies that use
targeted enrichment (►Table 3).33–37 Combining data from
multiple platforms surmounts some of the weaknesses inherent to different sequencing methods.33
Modiﬁcations to the basic NGS workﬂow that are
employed to study regulatory elements and RNA lead to
additional biases largely in the generation of DNA
fragments for sequencing and library preparation. For
instance, fragmentation of chromatin for CHIP-seq occurs in
a biased fashion with euchromatin being sheared more
readily than heterochromatin. In RNA sequencing, commonly
occurring biases include low complexity of transcripts,
uneven transcript coverage, and antisense artifacts. There
are methods that may be employed during library preparation and enrichment to help overcome some of the
weaknesses.38

Bioinformatics Platforms
In addition to the variety of sequencing platforms, multiple
bioinformatics pipelines exist to ﬁlter the raw data and create
the data ﬁles used for analysis. In the most simplistic terms,
NGS bioinformatics pipelines consist of an aligner and a
variant caller. During alignment, each read is aligned to the
best-ﬁt reference sequence using a statistical algorithm and is
assigned a mapping quality score.39 These alignments are
then fed to the variant caller for assignment of variant
presence and zygosity. In-depth comparisons have revealed
signiﬁcant differences in the overall output as well as the
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Table 3 Overview of next generation sequencing techniques
Description

Strengths

Weaknesses

Reference

Illumina HiSeq/Miseq

Reversible terminator
sequencing

• Less GC biases in GC poor areas
• More uniform coverage
• Better coverage in simple
repeat areas
• High sensitivity
• Low sample-to-sample variation

• GC biases in GC
rich areas
• Short read length

35,36,114

Complete genomics

DNA nanoball
sequencing

• Less GC bias in GC rich areas
• Highest total number of
bases covered
• High sensitivity

• GC biases in GC
poor areas
• Less uniform ge
nome coverage
• Large amount of
DNA required

36,114

ABI/SOLiD 4

Ligation

• Most speciﬁc in SNP calling

• Signiﬁcant GC
bias
• Less uniform coverage and smallest
percentage of genome coverage

36,114

Ion Torrent

Proton detection

• Fast
• Longer read length than
many technologies

• Higher error rates
• GC biases

35,36

Burrows Wheeler Aligner

Burrows–Wheeler
algorithm based

• Fast
• Memory efﬁcient
• Quality score to discard poorly
aligned reads

• Sensitivity highly
dependent on
quality of
sequence

40,115

Novoalign

Hash table-based
approach

• Good for long indels if mapping
quality is good
• Performs well with variety of
variant callers

• Sensitivity highly
dependent on
quality of
sequence

115

GSNAP

Hash table-based
approach—genome

• Genome indexing tool
• Detects complex variants and
splicing in individual reads

• Higher error per
centage on
mapped reads
requiring ﬁltering

115

Bowtie

Burrows–Wheeler
algorithm based

• Highest quality reads
• Fast

• Low SNP
detection rate

40,115

GATK

Gold standard

• Gold standard for SNP calling
• Most accurate for variants
• High sensitivity and positive
predictive value

• Time intensive

43,44

SAM tools

Manipulates alignments
in SAM format

• Accurate at lower read depths

• Bias toward
transition events
• Performs poorly
using multiple
sample algorithm

43,44

Alignment

Variant Caller

Abbreviations: GATK, genome analysis toolkit; GSNAP, Genomic Short-read Nucleotide Alignment Program; SAM, sequence alignment/map; SNP,
single nucleotide polymorphism; SOLiD, sequencing by oligonucleotide ligation and detection.

computational complexity and cost for different bioinformatics pipelines (►Table 3).39–45 Epigenomic and transcriptomic
analyses require additional data processing steps introducing
additional levels of complexity to the bioinformatics
pipeline.46

Genomics
Approach
The researcher generally selects one of three approaches
for sequencing, namely, targeted panels, whole-exome
Journal of Pediatric Genetics
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sequencing (WES), or whole-genome sequencing (WGS)
(►Table 4). Targeted gene panels sequence a select number
of genes and are often customized by the investigator to
include candidate genes. These genes may have been previously implicated in disease, part of the same biologic pathways as disease genes, or essential to the function of the tissue
or cell of interest.47 WES is technically a targeted panel, but,
due to its inclusion of all protein coding regions of the
genome, it allows for a more all-inclusive approach than a
targeted panel. It can examine known genes of interest as well
as novel candidates. WGS identiﬁes variants at almost all sites
in the genome. It is the most inclusive testing for the
identiﬁcation of disease-causing variants, as it includes noncoding sequence important to gene regulation.39 Often family
data including linkage analysis or prior genome-wide association studies results are utilized in data analysis to improve
results in genomic testing.48,49
In analyzing data from such experiments, researchers
often consider previous evidence for genetic pathogenicity.
Notably, gene pathogenicity and variant pathogenicity are
two different things and must be considered independently
by investigators. Recent studies have shown that the literature is rife with false-positive genetic associations and many
poorly validated pathologic variants are propagated in the
literature.10,50,51 These misclassiﬁcations have led to recent
attempts to establish more rigorous guidelines for variant
classiﬁcation including study design improvements, increased data sharing, and more comprehensive databases.

Applications
In nephrology, researchers have applied targeted NGS panels
and WES to study both Mendelian disease and recent more
complex diseases.1 For example, FSGS, a leading cause of
steroid-resistant nephrotic syndrome in children, is a genetically complex disease. Brown et al utilized linkage analysis in
a large pedigree of individuals affected by familial FSGS which
identiﬁed 17 areas on multiple chromosomes that had a
logarithm of odds score of >1. They then used WES in ﬁve
affected individuals and one unaffected individual to identify
a mutation in LIM homeobox transcription factor 1 β (LMX1B).
They discovered another family with a mutation in LMX1B in
their validation cohort of 91 patients with familial FSGS.52
Other studies used target gene panels to identify pathogenic
or likely pathogenic mutations in patients with steroidresistant nephrotic syndrome.7 Other diseases undergoing
extensive study with NGS include congenital anomalies of the
kidney and urinary tract (CAKUT), nephronophthisis and
other polycystic kidney disease, IgA nephropathy, and atypical hemolytic uremic syndrome.6,53–56

Epigenomics
Epigenomics is the study of the regulatory elements that
control gene expression using high throughput technology.
These elements are heritable and also reversible at the
cellular level. Regulatory elements control many developmental processes and modiﬁcation of these elements cause
disease.57,58 As these elements have diverse physical and
Journal of Pediatric Genetics
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chemical properties, many different methods have been
developed to optimize the epigenome mapping resolution
and overcome weaknesses inherent to the individual methods (►Table 4).59–61 Commonly studied elements include
histone modiﬁcations and DNA methylation. Histone modiﬁcations are important in the regulation of chromatin architecture and transcription. More than 100 different types of
histone modiﬁcation exist, including acetylation, methylation, and phosphorylation, all of which have been associated
with transcription regulation.62–65 Chromatin immunoprecipitation sequencing (CHIP-seq) is the most common technique used to study histone modiﬁcations and common
issues with this technique include antibody afﬁnity, GC
biases, and sample bias due to biased fragmentation.61,63,66
DNA methylation refers to the methylation of cytosine especially in CpG islands. DNA methylation plays a role in tumorigenesis and aging. More importantly, it is instrumental in
mammalian cell differentiation and development.63,67 Researchers use multiple different methods to describe the DNA
methylome.

Approach
Unlike genomics which studies DNA speciﬁcally, epigenomic
techniques must describe the architecture of chromatin, the
molecules that alter that architecture and how these traits
differ by cell type and change with environmental exposures
and/or time. Thus, investigators have developed multiple
different approaches to help address these questions. These
techniques suffer from the same sequencing biases as those of
genomic studies plus additional ones associated with the
presequencing procedures (►Table 4). Researchers may utilize these methods with either observational or experimental
designs. Traditional epidemiology study designs need modiﬁcations but may be used with epigenomic methods. Some
speciﬁc observational study designs include birth cohorts,
twin studies, and prenatal cohorts.68,69 Experimental approaches often examine changes in regulatory elements
before and after toxin or drug exposure in functional assays.

Application
Researchers have identiﬁed a role for both histone modiﬁcation and DNA methylation in many renal diseases.70 For
instance, genome-wide studies of methylation in subjects
with ADPKD reveal hypermethylation of PKD1 and other
genes involved in ion transport and cell adhesion. This hypermethylation led to decreased expression of these genes and
suggests a role for epigenetics in cystogenesis that may
explain the patchy nature of cyst formation.71 Histone modiﬁcation may also play a role in cyst formation. Knocking out
histone deacetylase 5 in pkd2 / mice led to a decrease in
cyst formation, suggesting a role for histone deacetylases
in cystogenesis.72 These examples show that even in diseases
with well-deﬁned genetic pathogenicity, epigenetic mechanisms may improve understanding of disease progression
and suggest avenues for new therapeutics. Other active
areas of epigenetic study in nephrology include renal
development, chronic kidney disease progression, and
autoimmunity.26,70,73
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Table 4 Next generation sequencing–based approaches and considerations for implementation
Description

Genomic target

Considerations

Reference

Targeted gene panels

DNA library preparation,
followed by targeted enrichment with probes
designed against only
genes of interest, MPS

DNA

• Less potential for novel
gene discovery
• Missing coverage in
genes of interest due
to gaps in probe design
or biases during
enrichment

116

WES

DNA library preparation,
followed by targeted enrichment with probes
designed for entire
exome (many commercially available exome
kits), MPS

DNA

• Missing coverage in
genes of interest due
to gaps in probe design
or biases during
enrichment
• Potential for incidental
ﬁndings

39,116

WGS

DNA library preparation
and MPS

DNA

• Less coverage than
whole exome or tar
geted panels
• Potential for incidental
ﬁndings

39,116

ChIP-seq

Cross-link proteins to
DNA, followed by fragmentation, immunoprecipitation, ampliﬁcation
of DNA, and MPS

Protein–DNA interactions
Histone modiﬁcation

• Chromatin conﬁguration introduces
sample-speciﬁc biases
• Ampliﬁcation biases

61,66

MNase-seq

Use of micrococcal nuclease to digest DNA until
it hits an obstruction like
nucleosome, then size
selection of fragments
the size of nucleosomes,
ampliﬁcation of DNA and
MPS

Nucleosome identiﬁcation and
quantiﬁcation

• Cleavage biases for ATrich sequences
• Size selection biases
• Variable TF binding
characteristics affects
enzymatic cleavage

66

DNase-seq

DNase I digests unprotected DNA, followed by
size selection, ampliﬁcation, and MPS

Maps open
chromatin

• Efﬁciency for TF binding sites varies with
fragment size
• Cleaves DNA in a
sequence-speciﬁc
manner
• Variable TF binding
characteristics affects
enzymatic cleavage

61,66

ATAC-seq

Transposase cuts DNA
while simultaneously incorporating adapters into
areas of open chromatin
followed by PCR and MPS

Factor occupation,
nucleosome position,
and chromatin
accessibility

• Cleavage biases based
on sequence
• Mitochondrial DNA
contamination
• Need for deep
sequencing

66,117

FAIRE-seq

Cross-linking of protein
and DNA with formaldehyde in vivo followed by
sonication, phenol-chloroform extraction and
MPS

Chromatin
accessibility

• Low signal-to-noise
ratio making
computation difﬁcult
• Need for very deep
sequencing
• Fixation efﬁciency
affects results

61,66,118

MethylC-seq

DNA fragmentation followed by ligation of
methylated adapters, size
selection using

DNA methylation

• Bias toward GC rich
areas of genome but
not necessarily CpG
islands

119

Epigenomic

(Continued)
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Table 4 (Continued)
Description

Genomic target

Considerations

Reference

• Mappability of short
reads

electrophoresis, bisulfate
conversion, ampliﬁcation
and MPS
Cross-linking protein and
DNA, followed by sonication, immunoprecipitation, ligation of linkers
with MME1 endonuclease, digestion with
MME1, pull down of biotinylated linkers with
streptavidin beads, ampliﬁcation of DNA tags,
and mapping to reference genome

Long-range chromatin interactions

• Limited by available
antibodies
• Inapplicable to repetitive regions of genome
• Identiﬁes transcription
factor binding sites but
cannot identify the
speciﬁc proteins in the
complex
• Multiple different analysis programs providing different results

61

RNA-seq

RNA isolated, fragmented, and copied into
cDNA

Total RNA or subpopulations including
mRNA, miRNA,
siRNA, lncRNA

• Need replicates
• GC biases
• Less accurate at tran
scription start sites

120

CLIP-seq

Cross-links RNA and protein, protein pulled down
by immunoprecipitation,
protein is removed and
RNA copied to cDNA,
then MPS

RNA–protein
interactions

• Need moderate
amount of input
material
• Low efﬁciency of crosslinking
• Potential bias due to
cross-linking

78

ChIA-PET

Transcriptomics

Abbreviations: ATAC-seq, assay for transposase-accessible chromatin using sequencing; CAPTURE-seq, RNA capture sequencing; ChIA-PET, chromatin
interaction analysis by paired-end tag sequencing; ChIP-seq, chromatin immunoprecipitation sequencing; CLIP-seq, cross-linking immunoprecipitation sequencing; DNase-seq, DNase I sequencing; FAIRE-seq, formaldehyde-assisted isolation of regulatory elements; iCLIP, individual-nucleotide
resolution cross-linking immunoprecipitation; LC-MS, liquid chromatography-mass spectrometry; MDB-seq, methylated DNA binding domain
sequencing; MeDip-seq, methylated DNA immunoprecipitation sequencing; MNase-seq, micrococcal nuclease sequencing; MPS, massive parallel
sequencing; NET-seq, native elongating transcript sequencing; PAR-CLIP, photoactivatable-ribonucleoside-enhanced cross-linking and immunoprecipitation; TF, transcription factor; WES, whole exome sequencing; WGS, whole genome sequencing.

Transcriptomics
Transcriptomics encompasses all testing that identiﬁes and
quantiﬁes RNA species. While microarray has traditionally
been used for gene expression, RNA-seq’s use has increased
dramatically over the past few years due to its low background noise, ability to identify novel transcripts, a large
dynamic range, and accuracy.59 The development of new high
throughput methods has also enabled researchers to examine
RNA: protein interactions providing further information
about RNA’s role in gene expression.

Approach
Common experimental designs that utilize NGS technology
include RNA-seq and cross-linking immunoprecipitation sequencing (CLIP-seq) (►Table 4). In RNA-seq, the sequencing
process is similar to genomic sequencing but with some
signiﬁcant distinctions. RNA-seq’s input is total RNA. Typically, during library preparation, RNA is separated by type using
oligonucleotides attached to magnetic beads. Reverse transcription converts RNA species into cDNA which is then
sequenced using NGS technology. RNA-seq utilizes NGSJournal of Pediatric Genetics
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based techniques to identify the spectrum of RNA species,
identify allelic imbalance, catalog alternative splicing patterns and posttranslational modiﬁcations, as well as quantify
RNA. Study designs may be similar to genomic studies when
identiﬁcation of variants and transcripts are of interest. RNAseq is also commonly implemented for gene expression
studies allowing for similar epidemiological approaches
and experimental designs to that of other regulatory elements.74 RNA-seq has several weaknesses including transcript bias introduced by sample preparation (3′ bias from
poly A tail selection), the necessity of deep sequencing to
capture lower expressed genes, and possibility of base errors
introduced during reverse transcription.75,76
RNA binding proteins (RBP) regulate posttranscriptional
expression. There are now several different high throughput
methods for studying RBPs including UV individual-nucleotide resolution cross-linking immunoprecipitation (iCLIP),
RNA co-immunoprecipitation, and photoactivatable-ribonucleoside-enhanced CLIP (PAR-CLIP). CLIP-seq is most commonly employed to study RBPs.77 In this approach, RBPs are
cross-linked to RNA using ultraviolet light. These complexes
are puriﬁed using immunoprecipitation. The unlinked
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Application
Both RNA-seq and CLIP-seq are relatively new technologies
and remain underutilized in pediatric nephrology. Recently,
investigators employed RNA-seq to describe the monocyte
transcriptome in systemic lupus erythematosus (SLE) with
associated glomerulonephritis. The monocyte was chosen for
this study because of its important role in the pathogenicity of
SLE. In this case–control design, investigators discovered that
several developmental genes were underexpressed in SLE,
suggesting that monocytes in SLE are more differentiated
compared with controls. Total transcription of protein coding
regions and antisense RNA were decreased in SLE subjects.
While most of the noncoding RNAs were decreased in SLE,
pri-miRNAs which prevent transcription were upregulated
corresponding to decreased expression observed in protein
coding genes.79 Other transcriptomic studies have revealed a
potential role for miRNA in lupus and have even begun to
examine the urine transcriptome in hopes of identifying
potential biomarkers for disease.80 Preliminary studies of
RNA-seq in ADPKD, acute kidney injury, and CAKUT have
demonstrated promise for elucidation of disease pathogenicity.81–83 One can easily imagine multiple uses for these
methods in the study of inherited renal disease.

Mass Spectrometry–Based Approaches
For the high throughput study of proteomics and metabolomics, MS has become the leading experimental method. It has
relatively high sensitivity and speciﬁcity. MS uses mass to
charge ratio (m/z) to identify substances. Typically a compound is dissolved in a solvent and ionized leading to its
fracture into charged fragments. These fragments are then
separated using a combination of electric and magnetic ﬁelds
and then detected as a spectrum based on their m/z. The
spectra are compared with other spectra in databases to
identify the compounds. Additionally, MS provides information about the relative abundance of the compounds. Different ionization methods and analyzers exist, each with their
own strengths and weaknesses (►Table 5).59,84 Notably,
analyzers are often used in tandem to allow improved
separation and identiﬁcation of material.84

Proteomics
Proteomics relies heavily on high throughput methods such
as MS to catalog all proteins in a cell or biological system.
Proteomic experiments are difﬁcult due to the issues mapping spectra and peptides to unique proteins, wide dynamic
range in abundance of proteins within the cell, and posttranslational modiﬁcations.85 It is estimated that only about two-

9

thirds of the proteins present in humans have been detected
using MS.59

Approach
The most common MS method utilized in proteomics is a
bottom-up approach using trypsin digestion and liquid chromatography (LC-MS/MS).84 Studies may aim to simply identify
proteins in a sample or more commonly investigators are
searching for quantitative differences between samples. In
quantitative experiments, one must consider both the biological variation and technical variation given MS run variability.
Two main approaches exist: one aims to characterize the
relative or absolute concentration of proteins and the other
aims to compare the changes in average abundance between
conditions. Downstream analysis of this data including class
discovery and class prediction often occurs. Class discovery
attempts to identify functional protein classes or biological
samples with similar protein proﬁles. Often systems biology
approaches are applied to accomplish this. Class prediction is
the use of protein abundance proﬁle to predict disease status
and is the ﬁrst step in establishing biomarkers.85

Application
To date, most studies of proteomics in pediatric nephrology
have focused on biomarker discovery. For instance, patients
with posterior urethral valves (PUV) are now often diagnosed
prenatally, but clinicians struggle with the extent of kidney
damage that the neonate will manifest. Klein et al86 examined
the power of urinary proteins to predict renal disease progression in PUV, ﬁrst taking an untargeted approach to identify
urine proteins that were differentially expressed in patients
with severe kidney disease/end-stage renal disease and those
without end-stage renal disease at 2 years. Then they validated
26 peptides in a separate cohort, limited these tests further,
and tested this algorithm in an independent cohort.86 Followup studies have utilized this early work to start predicting
outcomes for fetuses with PUV with the ultimate goal of using
this information to drive fetal intervention.87 These studies
demonstrate some of the guiding principles put forward in
clinical proteomic applications.27 Other nephrologic areas of
interest for proteomics include acute kidney injury, CAKUT,
allograft rejection, and renal Fanconi syndrome.88

Metabolomics
Metabolomics is the high throughput study of small molecules
such as peptides, amino, nucleic, and organic acids in a
biological system. MS and nuclear magnetic resonance
(NMR)-based techniques provide high throughput, sensitive,
and speciﬁc information about the metabolome. These experiments often examine potential biomarkers using blood, urine,
and serum. This review focuses on MS-based metabolomics,
but thorough reviews of NMR may be found elsewhere.89 The
metabolome is a heterogeneous mixture of molecules with
different physical and chemical properties preventing any one
MS analytic method from becoming the gold standard. MSbased metabolomic experiments have many similar limitations
and biases as are found in proteomics. These include
Journal of Pediatric Genetics
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proteins and RNA are digested leaving only a peptide bound to
the RNA. Then reverse transcription is performed and when
the RNA transcriptase encounters the peptide, a mutation
occurs or transcription prematurely stops. Bioinformatics
pipelines then determine the sites of these mutations and
where the truncated RNA aligns to identify the location of
RBPs.78
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Table 5 Overview of mass spectrometry methods
Description

Strengths

Weaknesses

Reference

Ionization methods
ESI

High voltage applied
to liquid, creating
aerosol

• Leaves the molecule intact

• Prone to ion
suppression

84,121

MALDI

MALDI matrix and
sample co-crystalize
and then matrix absorbs energy and
sample desorbs into
gas

• Rapid sample prep
• More tolerant of salts
and detergents

• Sensitivity and
peak resolution
suffer from suboptimal crystal
formation
• Not used for
absolute
quantiﬁcation

84

Triple quadrupole

Tandem quadrupole
MS using time varied
electric current using
DC and RF voltage

• Good reproducibility
• Low cost

• Limited resolution

84

Orbitrap

Uses electrostatic
force balanced by
centrifugal force to
trap ions

• Low cost
• High space charge capacity

• Slow scan speed
• Less mass resolution than FT-IRC

122

Time of ﬂight

M/Z determined by
TOF through vacuum
tube

• Detects largest molecules
• Fast
• Compatible with MS imaging

• -Less mass resolution than others

84

FT-IRC

Homogeneous application of magnetic
ﬁeld inducing cyclotron motion determined by m/z

• Highest mass resolving power
• Highest mass accuracy

• Slow
• Not used in
quantiﬁcation

84

Analyzers

Abbreviations: ATAC-seq, assay for transposase-accessible chromatin using sequencing; CAPTURE-seq, RNA capture sequencing; ChIA-PET, chromatin
interaction analysis by paired-end tag sequencing; ChIP-seq, chromatin immunoprecipitation sequencing; CLIP-seq, cross-linking immunoprecipitation sequencing; DNase-seq, DNase I sequencing; FAIRE-seq, formaldehyde-assisted isolation of regulatory elements; iCLIP, individual-nucleotide
resolution cross-linking immunoprecipitation; LC-MS, liquid chromatography-mass spectrometry; MDB-seq, methylated DNA binding domain
sequencing; MeDip-seq, methylated DNA immunoprecipitation sequencing; MNase-seq, micrococcal nuclease sequencing; MPS, massive parallel
sequencing; NET-seq, native elongating transcript sequencing; PAR-CLIP, photoactivatable-ribonucleoside-enhanced cross-linking and immunoprecipitation; TF, transcription factor; WES, whole exome sequencing; WGS, whole genome sequencing.

appropriate sample preparation, high analytic variability, and
destruction of material during experimentation.90

Approach
Most studies attempt to identify metabolites and quantify their
abundance. Often researchers use this information to detect
difference between two conditional states using classic epidemiological approaches and may also employ experimental
techniques especially in the area of pharmacology. Targeted
approaches are commonly implemented in the study of drugs
and other clinical biomarkers. This type of approach may utilize
knowledge of metabolic pathways to study changes in biological networks. Targeted approaches allow for increased sensitivity and speciﬁcity of metabolite identiﬁcation and improved
quantiﬁcation of products. Untargeted approaches are usually
hypothesis generating and require further studies for validation.91 Multiple in vitro study approaches attempt to identify
protein–metabolite interactions.59
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Application
Metabolomics especially on urine samples promises to
provide biomarkers and metabolic proﬁles that help
identify pathologic processes and potentially aid in prognosis in a noninvasive manner. For example, researchers
recently examined the urine metabolome of pediatric renal
transplant patients who underwent renal biopsy either as
part of their surveillance or due to increased creatinine. The
results revealed that a speciﬁc metabolic proﬁle could be
used to separate patients into three categories: acute T-cell
rejection, borderline rejection, and no rejection. Baseline
kidney function, inﬂammation, and pyuria did not affect
the reliability of this metabolic proﬁle.92 This study
demonstrates the promise of metabolic proﬁling in diagnosing renal disease states in a noninvasive manner. Other
recent studies have examined the metabolome as a possible
source of biomarkers in acute kidney injury and IgA
nephropathy.93
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Integration of Data
The development of high throughput omics methods has
shifted the burden of genetic disease from data generation to
data analysis. Each ﬁeld has made important discoveries
in isolation, but the richness of these data lies in its integration
to more fully depict biological systems. While NGS technologies allow exploration of the genomic footprint, regulation, and
transcription, the translation of this information into cellular
function in health and disease requires exploration of proteins
and metabolites. This incorporation of multiple different high
throughput methods to describe biological systems currently
underpins many principles of systems biology and has stimulated bioinformatics tools and statistical strategies to connect
data from these large datasets.94
Investigators have developed multiple methods in attempts
to integrate this omics information. There are two basic
approaches to integration: unsupervised and supervised
methods. Unsupervised methods ask one basic question. Is
there a pattern in this data? It is a hypothesis generating
technique. These processes tend to incorporate more of the
raw data. These tests do not necessarily contribute knowledge
to biological processes but instead provides fodder for a
supervised project. Supervised integration starts from a hypothesis and often requires further experimentation. Often
supervised approaches limit the dimensionality of the data.
There are multiple ways to carryout either a supervised or
unsupervised project. These include clustering, feature selection, prediction analysis, text mining, and pathway analysis.59
While these methods attempt to address integration of omics
data into a functional biologic picture, more methodological
work in both systems biology and omics is required to build
sophisticated hierarchal models of genetic disease.94

Functional Assays
To date, many of the systems biology approaches have utilized
functional models to obtain the appropriate datasets for inte-
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gration. Functional models are also used to validate disease
hypotheses generated through these techniques. In nephrology, in vitro methods using cell line, ex vivo methods with
murine kidney explants, and in vivo methods using model
organisms exist for the study of genomic processes (►Table 6).
Cell lines exist for almost all cells of the glomerulus and renal
tubules, and cell-based methods such as cellular reporter
assays including three-dimensional cell culture or tubulogenesis assays work well for renal diseases that primarily involve
only one cell type (e.g., nephronophthisis or ADPKD).4,95,96 Ex
vivo manipulation of murine renal explants or in vivo methods
such as conditional gene targeting holds promise for studying
more complex genetic diseases such as CAKUT4. Animal models commonly used with gene targeting methods include mice
and zebraﬁsh.97–99 Recent advances in the use of induced
pluripotent stem cells directly from affected patients’ ﬁbroblast
promise to provide a relatively easy genetic model system for
studying the effect of speciﬁc alleles on renal differentiation
and development but have yet to be available for use in
inherited renal disease.4 Researchers may also choose to apply
omics methods to these model systems, especially if the
relevant human tissue is inaccessible or when trying to study
only one particular cell type within an organ system. Without
more functional studies into genes and pathways identiﬁed
using omics data, the ability to accurately predict pathogenic
genetic mutations and describe the resultant molecular derangements identiﬁed in omics data will be incomplete.

Conclusion
Inherited renal disease is a leading cause of pediatric renal
morbidity and mortality. Recently, NGS has identiﬁed a
growing number of genes responsible for these diseases.
Continued development of high throughput technologies
provide further information on how genetic mutations manifest in disease. They offer new methods for diagnosis and
prognostication and possible targets for new therapeutics.
However, the omics ﬁelds are relatively young and further

Table 6 Functional assays for examining molecular pathways in renal disease
Description

Reference

Short-interfering RNA assays

Knockdown of candidate genes in transfected cells using siRNAs
that are homologous to the genes of interest

95

3D renal spheroid

Knockdown of candidate genes using siRNA in murine collecting
duct cell lines looking for change in shape of cilia which should be
spherical

96

Morpholinos

Antisense oligonucleotides complimentary to mRNA of interest
bind mRNA preventing protein synthesis

97

Inducible Cre-Lox–based animal models

Site-speciﬁc recombinase technology that introduces deletions,
insertions, translocations, and inversions into DNA. Targets
speciﬁc cell types or can be triggered by speciﬁc external stimulus

99

CRISPR/Cas9 systems

May target and conditionally knockdown any gene in a mouse
using guide RNA and Cas9 endonuclease to cut DNA at predetermined site of interest with the introduction of small indels or
different base pairs during the repair

98
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methodological development in the area of data processing
and statistical analysis will likely improve interpretation of
these experimental results. In order for translation of this
research into clinical application, more coordinated efforts
are needed in the ﬁeld. Datasets that include not only genetic
information but also protein and metabolite information will
allow for more integrated data analysis further illuminating
pathologic processes. Researchers need to focus on development of high throughput functional models to keep up with
the demand that these omics experiments generate. Standardized methods of data sharing and more widely shared
datasets will provide greater power to support genetic ﬁndings. Finally, greater education and awareness of these methodologies including their limitations among pediatric
nephrologists will lead to well-designed research projects
in a larger number of pediatric renal disease.
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